

ASX Announcement

Medibio Limited – 08/12/17



U.S. Department of Veterans Affairs White River Junction Medical Center Joins Medibio Depression Diagnostic Confirmatory Study to Support FDA Clearance

Sydney, Australia and Minneapolis, MN – 08 December 2017: Medibio Limited (MEB or the Company) (ASX: MEB) (OTCQB: MDBIF), a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions, is pleased to announce that the U.S. Veterans Affairs Medical Center located in White River Junction, Vermont (USA) will begin participating as a clinical research site enrolling participants in Medibio's Depression Diagnostic confirmatory study. The research study began enrolling in August, 2017 and will serve as the centerpiece of the company's FDA 510(k) *De Novo* submission.

The White River Junction VA study team will be led by Dr. Paul Holtzheimer. Dr. Holtzheimer joined the VA's National Center for PTSD in White River Junction, and conducts clinics at both the VA and Dartmouth-Hitchcock Medical Center. He has been working with the White River Junction VA Medical Center since 2011, when he joined Geisel School of Medicine at Dartmouth College and Dartmouth-Hitchcock Medical Center in Lebanon, NH as Associate Professor of Psychiatry and Surgery and Director of Mood and Anxiety Disorders Service. Prior to that, he was a member of faculty of the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine.

This confirmatory study follows the model of a previous successful exploratory study, which incorporated early FDA feedback on the study design to validate the Medibio analysis approach in identifying depression. The study is enrolling cohorts of both depressed and healthy controls, at sites in both the United States and Australia.

"The involvement of the White River Junction VA Medical center marks an important milestone. Building upon our initial Depression Diagnostic aid with patient monitoring, the VA's participation allows us to better understand indications such as PTSD and Generalized Anxiety Disorder in the next year in the interest of helping U.S. veterans and those who suffer from these and other conditions," says Jack Cosentino, CEO and Managing Director of Medibio.

For personal use only

“Participation in this study has great potential for improving the mental health care of Veterans and mental health care in general.” says Dr. Paul Holtzheimer.

White River Junction VA Medical Center, Vermont and U.S. Department of Veterans Affairs

White River Junction VA Medical Center, Vermont offers a variety of health services to meet the needs of our nation's Veterans. More information about access to care at the VA can be found at <https://www.accesstocare.va.gov/>

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), and U.S. offices in Minneapolis, MN and Palo Alto, CA. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

– ENDS –

Further Information: Website: www.medibio.com.au	
Medibio Shareholder Enquiries: Jack Cosentino CEO and Managing Director Medibio Limited jack.cosentino@medibio.com.au T: +1 (952) 465 4787	Australian Media Enquiries: Peter Taylor NWR Communications peter@nwrcommunications.com.au T: +61 (0) 412 036 231